Leerink PartnersRaises Price Target on Allergan (AGN) Following a MEDACorp Survey

Allergan (AGN) Acquires CONSTELLA Rights in Several Countries (IRWD)

October 27, 2015 6:12 AM EDT

Allergan (NYSE: AGN) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced that Allergan has acquired rights to CONSTELLA (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS® (linaclotide) in Mexico from Almirall.

Under the terms of the agreement, Allergan acquired an exclusive license for CONSTELLA in these countries. The license agreement includes the development and commercialization of CONSTELLA for the treatment of irritable bowel syndrome with... More

Controversial pharma CEO Martin Shkreli bails on Valeant bet

October 26, 2015 6:38 PM EDT

By Angela Moon

NEW YORK (Reuters) - The one-time hedge fund executive now running a biotech firm at the center of a drug-pricing controversy on Monday said he has bailed from a losing bet he made on another contentious drug maker: Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX).

On the day last week that Valeant shares plunged in response to a shortseller's accusation of accounting irregularities, Martin Shkreli, head of Turing Pharmaceuticals, took to Twitter to say he had bought shares of... More

Valeant Pharma (VRX) Short Interest Rose 49% Before Citron's 'Smoking Gun'

October 26, 2015 5:20 PM EDT

New data showed short interest over the past two-week period in Valeant Pharma (NYSE: VRX) increased 49.3% to 10,537,201 shares, Guggenheim analyst Louise Chen highlighted. Notably, the increase in short interest data was for the period ending 10/15/2015, nearly a week before Citron Research's "smoking gun" report on... More

Martin Shkreli Exits Long Valeant Pharma (VRX)/short Allergan (AGN) Trade for Loss of 3%

October 26, 2015 1:57 PM EDT

Martin Shkreli said he exited the long Valeant Pharma (NYSE: VRX) and short Allergan (NYSE: AGN) trade for a loss of 3%.

Exited the $AGN $VRX trade. 3% loss or so. Bad idea. Onward and upward.

Martin Shkreli (@MartinShkreli) October 26, 2015... More

Fund Should Consider Gaining Exposure to Valeant 'Collateral Damage' Stocks - Citron's Left

October 26, 2015 12:19 PM EDT

Citron Research's Andrew Left said in a Bloomberg interview that if he was a fund manager he would consider buying some of the stocks that saw collateral damage related to Valeant Pharma (NYSE: VRX).

Related Stocks:

Endo Int'l (NASDAQ:... More